A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome.

Trial Profile

A Phase II Trial of Trisenox Plus Thalomid as Treatment in Patients With Myelodysplastic Syndrome.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 May 2012

At a glance

  • Drugs Arsenic trioxide (Primary) ; Thalidomide
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2012 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 13 Oct 2009 Sponsor and lead trial centre (Cephalon) added as reported by ClinicalTrials.gov.
    • 24 Jan 2008 Status changed from in progress to discontinued according to NCT.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top